Last updated: September 1, 2026
Berinert is CSL Behring’s plasma-derived C1 esterase inhibitor for the on-demand treatment of acute hereditary angioedema attacks. Its commercial position remains durable because HAE is a rare, specialist-managed disease and Berinert has an established safety record, hospital familiarity, and broad international distribution. Its growth ceiling is constrained by the shift toward long-term prophylaxis, competition from subcutaneous and oral therapies, and the absence of separately disclosed product revenue in CSL’s public financial reporting.
What is Berinert and how is it used?
Berinert contains human plasma-derived C1 esterase inhibitor, also called C1-INH. In the United States, the product is approved for the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema in adult and pediatric patients. The labeled dose is 20 IU/kg administered by intravenous injection. Berinert is marketed as a reconstituted powder for intravenous use.[1]
| Attribute |
Berinert |
| Active ingredient |
Human plasma-derived C1 esterase inhibitor |
| Manufacturer |
CSL Behring |
| Disease |
Hereditary angioedema, primarily type I and type II |
| Primary role |
On-demand treatment of acute attacks |
| U.S. dosage |
20 IU/kg IV |
| U.S. approval |
September 29, 2009 |
| FDA pathway |
Biologics license application |
| U.S. product class |
Plasma-derived protein replacement |
| Main alternatives |
Ruconest, Firazyr, Kalbitor, Takhzyro, Orladeyo, Haegarda, Cinryze |
Berinert’s clinical value is highest in attacks involving the airway, abdomen, or face, where rapid treatment can reduce attack duration and hospitalization risk. Acute-use demand is episodic, while prophylaxis reduces attack frequency and can reduce reliance on rescue products.
How large is the Berinert market?
The addressable market is the global hereditary angioedema treatment market, which consists of a small patient population with high annual treatment costs. The market is commercially concentrated among a limited number of specialty pharmaceutical companies, with pricing influenced by disease severity, treatment setting, reimbursement, and the use of long-term prophylaxis.
CSL does not separately disclose Berinert revenue in its annual reports. It reports results at the CSL Behring segment level and discusses therapeutic franchises rather than providing a standalone Berinert income statement. Exact product revenue, gross margin, and unit volume therefore cannot be derived from CSL’s public filings.[2]
What drives Berinert demand?
Berinert demand is supported by several factors:
- Persistent diagnosis of HAE patients who require rescue therapy.
- Continued use in emergency departments and specialty centers.
- Physician familiarity with plasma-derived C1-INH.
- Clinical preference for treatment that replaces the deficient protein directly.
- International availability across European, Middle Eastern, Asian, and other markets.
- Use in patients who do not achieve adequate control with prophylactic therapy.
Demand is pressured by:
- Greater adoption of long-term prophylaxis.
- Subcutaneous administration through Haegarda and Takhzyro.
- Oral prophylaxis through Orladeyo.
- Home-treatment programs that favor convenient nonintravenous products.
- Reimbursement controls and site-of-care restrictions.
- Competition among multiple C1-INH and bradykinin-pathway products.
What is the financial trajectory for Berinert?
Berinert is likely a mature, cash-generative specialty product rather than a high-growth launch asset. Its financial trajectory is best characterized as stable to modestly pressured in the United States, with offsetting support from international markets and continued acute-treatment demand.
| Financial factor |
Effect on Berinert |
| Product maturity |
Limits organic growth but supports predictable demand |
| Rare-disease pricing |
Supports high revenue per treated patient |
| Prophylaxis adoption |
Reduces attack frequency and rescue utilization |
| International expansion |
Extends commercial life beyond the U.S. |
| Plasma supply |
Can affect cost of goods and production capacity |
| Hospital use |
Supports acute-treatment demand but increases reimbursement complexity |
| Competition |
Limits pricing power and share expansion |
| Product-specific disclosure |
CSL does not report standalone Berinert sales |
CSL Behring’s broader portfolio has continued to depend heavily on immunoglobulins, specialty plasma proteins, and rare-disease therapies. Berinert contributes to that portfolio as an established HAE product, but CSL’s financial disclosures do not permit a reliable calculation of its percentage of segment revenue.[2]
How does Berinert compare financially with newer HAE products?
Newer HAE products can generate stronger growth because they target prophylaxis, a larger recurring-treatment opportunity per patient. Berinert has a different revenue profile. It may be used intermittently, although some patients require frequent rescue treatment. Takhzyro and Orladeyo are positioned for scheduled long-term prevention, which can create more predictable recurring revenue.
| Product |
Company |
Administration |
Primary role |
Commercial pressure on Berinert |
| Berinert |
CSL Behring |
IV |
Acute treatment |
Baseline rescue competitor |
| Haegarda |
CSL Behring |
Subcutaneous |
Long-term prophylaxis |
Internal substitution risk |
| Cinryze |
Takeda |
IV |
Long-term prophylaxis |
Competes within C1-INH class |
| Ruconest |
Pharming |
IV |
Acute treatment |
Recombinant alternative |
| Firazyr |
Takeda |
Subcutaneous |
Acute treatment |
Convenience competitor |
| Kalbitor |
Dyax/Takeda |
Subcutaneous |
Acute treatment |
Administration and safety trade-off |
| Takhzyro |
Takeda |
Subcutaneous |
Long-term prophylaxis |
Major prophylaxis competitor |
| Orladeyo |
BioCryst |
Oral |
Long-term prophylaxis |
Convenience-driven competitive threat |
When does Berinert lose exclusivity?
Berinert’s U.S. orphan-drug exclusivity expired on September 29, 2016, seven years after FDA approval. Orphan exclusivity prevented FDA approval of the same drug for the same indication during that period, but it did not create permanent market exclusivity.[1,3]
The product remains protected by its biologics license, manufacturing controls, regulatory know-how, trademarks, supply chain, and potentially jurisdiction-specific patents. Expiration of orphan exclusivity did not automatically create an FDA-approved competing biologic.
| U.S. milestone |
Date or status |
| FDA approval |
September 29, 2009 |
| Seven-year orphan exclusivity |
Ended September 29, 2016 |
| Current FDA regulatory framework |
Biologics Price Competition and Innovation Act pathway |
| Orange Book listing |
Not the principal U.S. patent reference for biologics |
| Purple Book relevance |
Yes |
| FDA-approved interchangeable biosimilar |
None identified through June 2024 |
What patents protect Berinert?
Berinert is regulated as a biologic, so its U.S. patent analysis differs from that of a conventional small-molecule drug. The Orange Book generally does not provide the central patent record for a biologics license. The FDA’s Purple Book identifies licensed biological products and biosimilar relationships, but it is not a complete replacement for a full patent-family search.[4]
The commercially relevant protection layers include:
- Biologic regulatory exclusivity. Berinert’s original U.S. orphan exclusivity expired in 2016.
- Manufacturing know-how. Plasma collection, donor screening, viral inactivation, purification, quality control, and batch-release systems are difficult to replicate.
- Formulation and stability technology. Patents may cover excipient systems, lyophilized formulations, storage, reconstitution, or delivery characteristics.
- Process patents. C1-INH purification and viral-clearance processes can create country-specific barriers.
- Trademark protection. The Berinert brand remains commercially important in a specialist market.
- Regulatory and clinical experience. Safety databases, physician familiarity, and treatment-center integration create protection not captured by a patent expiration date.
A definitive patent-expiration schedule for Berinert cannot be inferred from the FDA label, CSL annual reports, or the Purple Book. No current U.S. Orange Book patent list provides a complete Berinert patent estate.
What formulation patents protect Berinert?
The product’s lyophilized presentation, reconstitution process, excipient system, container closure, storage conditions, and viral-safety process may be covered by patent families or confidential manufacturing know-how. Those protections are separate from the original approval and may expire at different times across jurisdictions.
For commercial purposes, the key barrier is often process reproducibility rather than a single composition-of-matter patent. A competitor must establish a consistent, safe, high-purity plasma-derived product and demonstrate comparability or clinical efficacy under the applicable regulatory pathway.
Are biosimilars or generic versions of Berinert a major risk?
There is no conventional generic pathway for Berinert. A competitor would need to pursue a biologics pathway, generally involving a biosimilar or a standalone biologics license application. Plasma-derived proteins can be difficult biosimilar targets because the source material, purification process, post-translational characteristics, impurity profile, and viral-clearance steps affect the final product.
Through June 2024, no FDA-approved biosimilar to Berinert was identified in the Purple Book. The more immediate competitive risk comes from alternative HAE mechanisms and delivery systems rather than direct biosimilar substitution.[4]
What manufacturing barriers limit biosimilar entry?
The principal barriers include:
- Access to qualified human plasma.
- Donor screening and traceability.
- Viral inactivation and removal.
- Control of protein purity and activity.
- Batch-to-batch consistency.
- Specialized fill-finish and cold-chain infrastructure.
- Clinical and analytical comparability.
- Reimbursement acceptance in a rare-disease market.
These barriers can delay entry even after regulatory exclusivity and older patents have expired.
Which companies are challenging Berinert commercially?
The most important competitors are Takeda, Pharming, BioCryst, and CSL Behring itself through adjacent products.
CSL Behring versus Takeda
CSL competes internally through Berinert for acute treatment and Haegarda for prophylaxis. Takeda’s Cinryze, Firazyr, and Takhzyro cover both acute and preventive HAE care. Takhzyro is particularly important because it can reduce the number of acute attacks requiring rescue treatment.[5]
CSL Behring versus BioCryst
BioCryst’s Orladeyo is an oral prophylactic therapy. Oral administration addresses a major weakness of injectable C1-INH products and creates a risk of gradual substitution in patients who prioritize convenience and attack prevention.[6]
CSL Behring versus Pharming
Ruconest is a recombinant C1-INH product administered intravenously for acute attacks. It competes on mechanism and acute use, although its recombinant origin differentiates it from Berinert’s plasma-derived supply chain.[7]
What is the FDA and Orange Book status of Berinert?
Berinert is FDA-approved under a biologics license. The FDA-approved indication covers acute HAE attacks, including abdominal, facial, and laryngeal attacks. The FDA label does not establish Berinert as a prophylactic product in the United States.[1]
The Orange Book is primarily used for approved small-molecule drug products and their listed patent and exclusivity information. For Berinert, the relevant U.S. regulatory sources are the FDA biologics license, the product label, the Purple Book, and patent databases.
| Regulatory issue |
Berinert status |
| FDA approval |
Active biologics approval |
| Approved use |
Acute HAE attacks |
| Orphan exclusivity |
Expired in 2016 |
| Orange Book patent listing |
Not the primary record |
| Purple Book entry |
Relevant |
| Biosimilar competition |
None identified through June 2024 |
| Pediatric use |
Included in current U.S. labeling |
What patent litigation and Paragraph IV challenges affect Berinert?
No major publicly documented U.S. Paragraph IV litigation involving Berinert is identified through June 2024. Paragraph IV litigation is principally associated with abbreviated new drug applications for small-molecule products. A biologic competitor would generally use the biosimilar framework or pursue a separate BLA rather than file a conventional ANDA Paragraph IV certification.
The absence of a reported Paragraph IV case does not eliminate competition risk. A future entrant could challenge individual process, formulation, or use patents, or proceed through a regulatory route that does not depend on the same patent-certification framework.
No major public Berinert settlement agreement or license agreement governing U.S. biosimilar entry was identified in the cited public sources.
How does Berinert’s geographic coverage affect its commercial life?
Berinert’s international footprint extends its commercial life beyond the U.S. orphan-exclusivity period. European and other national markets apply different rules for supplementary protection, patent enforcement, reimbursement, procurement, and biologic substitution.
The product’s global opportunity is shaped by:
- HAE diagnosis rates.
- Availability of specialist treatment centers.
- National reimbursement.
- Hospital procurement systems.
- Local plasma-product regulation.
- Access to home infusion.
- Competition from regional C1-INH and bradykinin-pathway products.
In lower-diagnosis markets, commercial expansion depends less on share capture and more on improving disease recognition and access to specialist care.
What generic launch scenarios exist for Berinert?
Scenario 1: No direct biologic entrant
This is the lowest-risk scenario for CSL. Berinert retains its established acute-treatment base while prophylactic products absorb incremental growth.
Scenario 2: A biosimilar or follow-on C1-INH product launches
The entrant would initially target price-sensitive payers and hospitals. Berinert could retain share through physician familiarity, supply reliability, and quality history. Price erosion would depend on interchangeability, procurement rules, and payer incentives.
Scenario 3: Acute-use substitution accelerates
Subcutaneous acute therapies, improved self-administration, or new oral products could reduce IV rescue demand. This would put greater pressure on Berinert than a direct biosimilar would.
Scenario 4: Prophylaxis expands without eliminating rescue demand
This is the most commercially plausible base case. Patients on Takhzyro, Orladeyo, or Haegarda still need rescue treatment for breakthrough attacks. Berinert remains part of the treatment pathway, but utilization per patient may decline.
How strong is Berinert’s patent and commercial estate?
Berinert has a moderate-to-strong commercial defense but a less certain late-life patent position. Its strongest protections are manufacturing complexity, regulatory experience, brand recognition, clinical familiarity, and supply infrastructure. Its weakest point is the expiration of orphan exclusivity and the absence of a clearly identifiable, publicly consolidated U.S. patent estate that would block all future biologic competition.
The product’s long-term value therefore depends more on franchise management than on a single remaining patent. CSL can defend its position through Berinert, Haegarda, plasma sourcing, treatment-center relationships, and global regulatory coverage.
What is the outlook for Berinert revenue?
The likely trajectory is mature and defensible, with modest downside from prophylaxis and convenience-driven substitution. Revenue can remain resilient if:
- HAE diagnosis continues to improve.
- Breakthrough attacks remain clinically significant.
- CSL maintains plasma supply and manufacturing reliability.
- Berinert remains reimbursed for emergency and home treatment.
- International markets offset U.S. maturation.
- CSL uses its broader HAE portfolio to retain patients within the franchise.
The main downside factors are conversion from acute treatment to preventive therapy, competitive rebate pressure, and replacement of IV products by subcutaneous or oral options. CSL’s public reporting does not support a product-level revenue forecast or a precise valuation of Berinert independently from the broader CSL Behring portfolio.
Key Takeaways
- Berinert is a mature, FDA-approved plasma-derived C1-INH product for acute HAE attacks.
- U.S. orphan exclusivity expired on September 29, 2016.
- CSL does not separately disclose Berinert revenue, margins, or unit volume.
- No FDA-approved Berinert biosimilar was identified through June 2024.
- The main commercial threat is prophylaxis and convenience, not traditional generic substitution.
- Takhzyro, Orladeyo, Haegarda, Cinryze, Ruconest, and Firazyr define the competitive field.
- Manufacturing, plasma supply, regulatory history, and specialist adoption provide meaningful barriers to entry.
- Berinert is likely to remain a durable specialty product, but its growth rate should trail newer preventive HAE therapies.
FAQs
Is Berinert still under patent protection?
Berinert’s original U.S. orphan exclusivity expired in 2016. Any remaining patent protection is likely to depend on specific formulation, process, manufacturing, or use claims in individual jurisdictions. A single public expiration date does not describe the full estate.
Can a patient switch from Berinert to Takhzyro?
The products have different roles. Berinert treats acute attacks, while Takhzyro is used for long-term prophylaxis. Patients receiving Takhzyro may still require an acute rescue therapy.
Is Berinert interchangeable with Haegarda?
No. Both are plasma-derived C1-INH products from CSL Behring, but they have different FDA-approved uses, administration methods, dosing regimens, and clinical positioning.
Does Berinert face competition from oral HAE drugs?
Yes. Orladeyo provides oral prophylaxis and can reduce attack frequency, potentially lowering demand for acute rescue treatment. It does not function as a direct generic replacement for Berinert.
What is the largest long-term risk to Berinert sales?
The largest risk is a change in treatment patterns toward effective long-term prophylaxis, particularly subcutaneous or oral products that reduce acute attacks and make intravenous rescue therapy less frequently necessary.
References
- U.S. Food and Drug Administration. (2023). Berinert: Prescribing information. CSL Behring LLC.
- CSL Limited. (2023). Annual report 2023.
- U.S. Food and Drug Administration. (2024). Orphan drug designations and approvals database.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
- U.S. Food and Drug Administration. (2023). Takhzyro: Prescribing information. Takeda Pharmaceuticals U.S.A., Inc.
- U.S. Food and Drug Administration. (2023). Orladeyo: Prescribing information. BioCryst Pharmaceuticals, Inc.
- U.S. Food and Drug Administration. (2022). Ruconest: Prescribing information. Pharming Americas B.V.
